Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis

Fig 7 Trial sequential analysis (cumulative meta-analysis) assessing effect of antithrombin III in critically ill patients. Cumulative z curve (red dashed line) does not cross sequential monitoring boundary constructed for sample size of 3317 patients in meta-analysis (blue line) with relative risk reduction of 10% (from 48.5% to 43.2%) (α=0.05) and power of 80% (β=0.20). With total number of accrued participants in randomised trials being 3458, we can reject relative risk reduction of 10% at 80% power